

KWON YOUNG  
Form 4  
July 16, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
KWON YOUNG

(Last) (First) (Middle)

C/O MOMENTA  
PHARMACEUTICALS, INC., 301  
BINNEY STREET

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
MOMENTA  
PHARMACEUTICALS INC  
[MNTA]

3. Date of Earliest Transaction  
(Month/Day/Year)  
07/12/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
SVP, Corporate Development

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/12/2018		M <sup>(1)</sup>	A	11,000	D	
Common Stock	07/12/2018		S <sup>(1)</sup>	D	11,000	D	
Common Stock	07/12/2018		M <sup>(1)</sup>	A	5,500	D	
Common Stock	07/12/2018		S <sup>(1)</sup>	D	5,500	D	

Edgar Filing: KWON YOUNG - Form 4

					(2)		
Common Stock	07/12/2018	M <sup>(1)</sup>	6,000	A	\$ 12.58	143,623	D
Common Stock	07/12/2018	S <sup>(1)</sup>	6,000	D	\$ 25.41	137,623	D
Common Stock	07/12/2018	M <sup>(1)</sup>	6,000	A	\$ 17.96	143,623	D
Common Stock	07/12/2018	S <sup>(1)</sup>	6,000	D	\$ 25.41	137,623	D
Common Stock	07/12/2018	M <sup>(1)</sup>	4,000	A	\$ 13.02	141,623	D
Common Stock	07/12/2018	S <sup>(1)</sup>	4,000	D	\$ 25.41	137,623	D
Common Stock	07/12/2018	M <sup>(1)</sup>	2,000	A	\$ 21.56	139,623	D
Common Stock	07/12/2018	S <sup>(1)</sup>	2,000	D	\$ 25.91	137,623	D
Common Stock	07/12/2018	S <sup>(1)</sup>	11,999	D	\$ 25.4	125,624	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
Stock Option(Right)	\$ 13.26	07/12/2018		M <sup>(1)</sup>	11,000	02/22/2015 02/22/2021	Common Stock

to Buy)									
Stock Option(Right to Buy)	\$ 15.44	07/12/2018	M <sup>(1)</sup>	5,500	02/14/2016	02/14/2022	Common Stock	5,500	
Stock Option(Right to Buy)	\$ 12.58	07/12/2018	M <sup>(1)</sup>	6,000	02/19/2017	02/19/2023	Common Stock	6,000	
Stock Option(Right to Buy)	\$ 17.96	07/12/2018	M <sup>(1)</sup>	6,000	02/18/2018	02/18/2024	Common Stock	6,000	
Stock Option(Right to Buy)	\$ 13.02	07/12/2018	M <sup>(1)</sup>	4,000	05/18/2018	02/18/2025	Common Stock	4,000	
Stock Option(Right to Buy)	\$ 21.56	07/12/2018	M <sup>(1)</sup>	2,000	05/11/2018	08/11/2025	Common Stock	2,000	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KWON YOUNG C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE, MA 02142			SVP, Corporate Development	

## Signatures

/s/ Alejandra Carvajal as attorney  
in fact

07/16/2018

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This transaction was effected pursuant to a Rule 10b5-1 trading plan.

This transaction was executed in multiple trades at prices ranging from \$24.90 to \$25.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

(3) This transaction was executed in multiple trades at prices ranging from \$25.90 to \$25.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

(4) This transaction was executed in multiple trades at prices ranging from \$24.90 to \$25.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

## Edgar Filing: KWON YOUNG - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.